Last reviewed · How we verify
Wegovy ®
Wegovy® is a marketed drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, supported by robust clinical trial results. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Wegovy ® |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
- A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults (PHASE1)
- A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
- Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
- JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity (PHASE4)
- A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
- A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
- The Effects of Semaglutide on Body Composition and Performance in Military Personnel (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wegovy ® CI brief — competitive landscape report
- Wegovy ® updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI